Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Degarelix Powder and Solvent for Suspension for Injection.

Trial Profile

Degarelix Powder and Solvent for Suspension for Injection.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2012

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 May 2009 Additional locations (Romania, Hungary, Czech Republic) identified as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top